SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“Save the date!
Thursday 4 December 2025 – 18:00 CET
The next webinar within the EU-funded Definitive Trial will focus on the biological foundations and clinical management of anti-HER2 therapies in breast cancer.
Leading experts will explore the molecular mechanisms behind HER2-targeted treatments and their impact on patient outcomes, addressing both scientific advances and the challenges of managing therapy-related toxicities.
Stay tuned and join the discussion.
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).”
More posts featuring SPCC.